Literature DB >> 2542998

Receptors for substance P and related neurokinins.

D Regoli1, G Drapeau, S Dion, P D'Orléans-Juste.   

Abstract

The most widely used smooth muscle preparations for neurokinin bioassays have been critically analyzed in order to determine whether neurokinins act directly or by the intermediary of other natural agents. Indeed, part of the contraction of the GPI in response to neurokinins appears to be mediated by acetylcholine and possibly prostaglandins. Active metabolites of the arachidonic acid cascade also intervene in the response of the HUB. Neurokinins produce relaxation of the DCA by stimulating the release of a vascular smooth muscle relaxing factor from the endothelium. In the other preparations (the RD, the RPA without endothelium and the RPV) neurokinins may act directly on the smooth muscle fibers. Neurokinins produce their biological effects by activating specific receptors. Three different receptor types, one for each mammalian neurokinin, have been identified by using four groups of natural peptide sequences and some selective agonists. The receptor for SP is particularly sensitive to SP and physalaemin and shows higher affinity for the whole natural peptides (SP, NKA) than for their C-terminal fragments. The receptor for neurokinin A is highly sensitive to NKA and eledoisin: it shows high affinity for heptapeptide fragments such as NKA4-10 and SP5-11. The receptor for NKB is sensitive to NKB and kassinin more than to the other natural peptides and their fragments. The natural peptides show however little selectivity. Synthetic analogues active on a single receptor type (selective agonists) have been used to find out whether the responses of the isolated organs are due to the activation of one or more than one receptor. It has been found that the GPI, the RD and the HUB contain all three or at least two receptors, while the DCA has only the NK1, the RPA has only the NK2 and the RPV only the NK3 type. Binding sites specific for each neurokinin have been identified in brain and peripheral organs with accurate biochemical assays, using labeled neurokinins. Competitive displacement assays have been performed with a variety of neurokinin-related peptides, and their Ki have been determined. By plotting Ki values against the ED50, estimated from biological assays, positive significant correlations have been found for the monoreceptor (DCA, RPA, RPV) but not for the multiple receptor systems (GPI, RD, HUB). This suggests that pharmacological receptors may be identical with the recognition sites which bind the labeled neurokinins. The availability of monoreceptor systems and of selective agonists opens the way for the identification of potential antagonists and accurate estimation of their affinities.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2542998     DOI: 10.1159/000138512

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  15 in total

1.  Mutational analysis and molecular modeling of the nonapeptide hormone binding domains of the [Arg8]vasotocin receptor.

Authors:  H Hausmann; A Richters; H J Kreienkamp; W Meyerhof; H Mattes; K Lederis; H Zwiers; D Richter
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

2.  Functional evidence for NO-synthase activation by substance P through a mechanism not involving classical tachykinin receptors in guinea-pig ileum in vitro.

Authors:  R Garcia-Villar; C Dupuis; J P Martinolle; J Fioramonti; L Buéno
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

3.  Tachykinin NK1 and NK2 receptors mediate inhibitory vs excitatory motor responses in human isolated corpus cavernosum and spongiosum.

Authors:  Riccardo Patacchini; Guido Barbagli; Enzo Palminteri; Massimo Lazzeri; Damiano Turini; Carlo Alberto Maggi
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

4.  Further evidence for the existence of NK2 tachykinin receptor subtypes.

Authors:  R Patacchini; M Astolfi; L Quartara; P Rovero; A Giachetti; C A Maggi
Journal:  Br J Pharmacol       Date:  1991-09       Impact factor: 8.739

5.  LncRNA RMRP silence curbs neonatal neuroblastoma progression by regulating microRNA-206/tachykinin-1 receptor axis via inactivating extracellular signal-regulated kinases.

Authors:  Juntao Pan; Da Zhang; Jiao Zhang; Pan Qin; Jiaxiang Wang
Journal:  Cancer Biol Ther       Date:  2018-12-24       Impact factor: 4.742

6.  Higher potency of RP 67580, in the mouse and the rat compared with other nonpeptide and peptide tachykinin NK1 antagonists.

Authors:  J C Beaujouan; E Heuillet; F Petitet; M Saffroy; Y Torrens; J Glowinski
Journal:  Br J Pharmacol       Date:  1993-03       Impact factor: 8.739

7.  Characterization of a tachykinin peptide NK2 receptor transfected into murine fibroblast B82 cells.

Authors:  P L van Giersbergen; S A Shatzer; A K Henderson; J Lai; S Nakanishi; H I Yamamura; S H Buck
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-01       Impact factor: 11.205

8.  Substance P-induced fibrinolysis in the forearm of healthy humans.

Authors:  M Fanciullacci; S Fedi; M Alessandri; U Pietrini
Journal:  Experientia       Date:  1993-03-15

9.  Characterization of the receptor mediating relaxation to substance P in canine middle cerebral artery: no evidence for involvement of substance P in neurogenically mediated relaxation.

Authors:  C M Stubbs; G J Waldron; H E Connor; W Feniuk
Journal:  Br J Pharmacol       Date:  1992-04       Impact factor: 8.739

10.  Human neuronal cells (NT2-N) express functional substance P and neurokinin-1 receptor coupled to MIP-1 beta expression.

Authors:  Yuan Li; Steven D Douglas; David E Pleasure; Jianping Lai; Changjiang Guo; Peter Bannerman; Marge Williams; Wenzhe Ho
Journal:  J Neurosci Res       Date:  2003-02-15       Impact factor: 4.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.